SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of NGM Biopharmaceuticals, Inc. (Nasdaq – NGM)
BALA CYNWYD – February 26, 2024 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of NGM Biopharmaceuticals, Inc. (“NGM Bio” or the “Company”) (Nasdaq – NGM) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the acquisition of the Company by affiliates of The Column Group, LP (together with certain of The Column Group, LP’s affiliates, the “TCG Stockholders”). Under the terms of the transaction, TCG Stockholders will acquire all outstanding shares of NGM Bio common stock for $1.55 per share in cash.
The investigation concerns whether the NGM Bio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company’s shareholders. For example, the deal consideration is below the 52-week high of $4.83 for the Company’s stock.
If you own shares of NGM Bio stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.